30th Annual ROTH Conference
March 11-14, 2018
Ritz Carlton, Dana Point, CA
ROTH Capital Partners' 30th Annual Conference is one of the largest of its kind in the United States. With roughly 500 participating companies and over 4,000 attendees, Roth will feature presentations from hundreds of public and private companies in a variety of sectors including health care; technology, Internet and media; cleantech, industrial growth and solar; consumer; oil and gas/mining and minerals; and business services. The three-and-a-half day event will include company presentations and small group meetings, as well as panels, entertainment and more. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a must attend event for anyone working in the small and mid-cap space. For more information visit www.Roth.com
KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals (NASDAQ: KALV) is a clinical-stage pharmaceutical company that discovers, develops, and commercializes small molecule protease inhibitors to treat diseases with significant unmet need. The company's proprietary portfolio comprises of novel, small molecule plasma kallikrein inhibitors primarily targeting hereditary angioedema ("HAE") and diabetic macular edema ("DME"). KalVista's most advanced program, KVD001, has successfully completed its first-in-human study in patients with DME and commenced a phase 2 clinical trial in 2017. For more information, visit the company's website at www.kalvista.com.
KemPharm (KMPH)
KemPharm (NASDAQ: KMPH) is a clinical-stage specialty pharmaceutical company that discovers and develops new proprietary prodrugs in the United States through its proprietary Ligand Activated Therapy ("LATTM") platform technology. KemPharm's co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release and effect profiles for the treatment of ADHD. Apadaz™, the company's product candidate of benzhydrocodone, a prodrug of hydrocodone and acetaminophen, has received FDA approval. The company is also involved in developing KP201/IR (APAP-free), an IR formulation of KP201 without APAP for the short-term management of acute pain. For more information, visit the company's website at www.kenpharm.com.
Krystal Biotech (KRYS)
Krystal Biotech (NASDAQ: KRYS) is a gene therapy company focused on developing and commercializing novel treatments for patients suffering from dermatological diseases. The company's lead product candidate, KB103, is currently in preclinical development and seeks to use gene therapy to treat Epidermolysis Bullosa. KB103 has been engineered employing the company's STAR platform to deliver functional human COL7A1 genes directly to the patients' dividing and non-dividing skin cells. The company's pipeline also includes therapies in development to treat Netherton Syndrome, Ichthyosis Vulgaris, and Atopic Dermatitis. For more information, visit the company's website at www.krystalbio.com.
Kush Bottles (KSHB)
Kush Bottles (OTC: KSHB) is a provider of packaging, supplies, vaporizers, accessories and branding solutions for the regulated cannabis industry. Kush Bottles provides unique products and services for both businesses and consumers. The company has sold more than 100 million units and now regularly services more than 5,000 legally operated medical and adult-use dispensaries, growers, and producers across North America, South America, and Europe. Kush Bottles has facilities in the three largest U.S. cannabis markets and a local sales presence in every major U.S. cannabis market. For more information, visit the company's website at www.kushbottles.com.
Lakeland Industries (LAKE)
Lakeland Industries (NASDAQ: LAKE) manufactures and sells a comprehensive line of safety garments and accessories for the industrial protective clothing market. The company's products are sold by a direct sales force and through independent sales representatives to a network of over 1,000 safety and mill supply distributors. In addition, Lakeland supplies federal, state, and local government agencies, fire and police departments, airport crash rescue units, the Department of Defense, the Centers for Disease Control and Prevention, and many other federal and state agencies. For more information, visit the company's website at www.lakeland.com.
Landec (LNDC)
Landec (NASDAQ: LNDC) designs, develops, manufactures and markets differentiated health and wellness products in food and biomaterials markets. Landec's food business includes Apio, Inc. and O Olive, Inc. Apio™ provides branded, packaged fresh vegetables in North America utilizing its proprietary BreatheWay® packaging technology to naturally extend the shelf life of fresh produce. The company recently acquired O Olive Oil®, an organic and natural producer and marketer of olive oils and vinegars under the O brand. Lifecore Biomedical, the company's biomaterial business, is a fully integrated Contract Development and Manufacturing Organization ("CDMO") that provides expertise and capabilities in fermentation, specialty formulation, aseptic filling and final packaging for FDA regulated medical devices and drugs to customers for applications in a wide array of markets including Ophthalmic, Orthopedic and Oncology. For more information, visit the company's website at www.landec.com.
Lannett Company (LCI)
Lannett Company (NYSE: LCI) develops, manufactures, packages, markets and distributes generic versions of brand pharmaceutical products in the United States. It offers solid oral, extended release, topical, nasal and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel and injectable dosages. The company provides its products for various medical indications comprising glaucoma, muscle relaxant, migraine, anesthetic, congestive heart failure, gastrointestinal, cardiovascular, thyroid deficiency, central nervous system, urinary, dryness of the mouth, gout, hypertension and gallstone. For more information, visit the company's website at www.lannett.com.
Las Vegas Sands (LVS)
Las Vegas Sands (NYSE: LVS) together with its subsidiaries, develops, owns, and operates integrated resorts in Asia and the United States. Starting with a single property in 1990, the company's footprint now extends worldwide with properties in Las Vegas, Macao, Pennsylvania and Singapore. The company is engaged in developing and operating some of the largest and most complex business and leisure properties. Las Vegas Sands' integrated resorts include accommodations, gaming, entertainment and retail, convention and exhibition facilities, celebrity chef restaurants, and other amenities. For more information, visit the company's website at www.sands.com.
Layne Christensen (LAYN)
Layne Christensen (NASDAQ: LAYN) is a global water management, construction, and drilling company that provides responsible solutions for water, mineral and energy challenges. The Woodlands, Texas-based company operates throughout North America, Africa, Australia, Europe, Brazil, and in other South American countries through its affiliates. Layne solutions comprise of identifying and developing a new water source, delivering usable water to communities and facilities around the world, recycling water from oil and gas resources, rehabilitating an existing pipeline, or safely returning wastewater to the natural environment. For more information, visit the company's website at www.layne.com.
LeMaitre Vascular (LMAT)
LeMaitre Vascular (NASDAQ: LMAT) develops, manufactures and markets medical devices and implants for the treatment of peripheral vascular disease worldwide. The company provides angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; carotid shunts to temporarily divert or shunt blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and powered phlebectomy devices that enable less invasive removal of varicose veins. It also offers embolectomy catheters to remove blood clots from arteries or veins, and occlusion catheters that temporarily occlude blood flow. For more information, visit the company's website at www.lemaitre.com.
Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals (NASDAQ: LGND) is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The company's Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. The company partners with other pharmaceutical companies to ultimately generate further revenue. Such alliances, licenses and other business relationships include Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly. For more information, visit the company's website at www.ligand.com.
LightPath Technologies (LPTH)
LightPath Technologies (NASDAQ: LPTH) is a global, vertically integrated provider of optics, photonics and infrared solutions for the industrial, defense, telecommunications, testing and measurement, and medical industries. LightPath designs, manufactures, and distributes proprietary optical and infrared components including molded glass aspheric lenses and assemblies, infrared lenses and thermal imaging assemblies, fused fiber collimators, and gradient index GRADIUM® lenses. LightPath's suite of offerings also includes custom optical assemblies with full engineering design support. The company is headquartered in Orlando, Florida, with manufacturing and sales offices in New York, Latvia and China. For more information, visit the company's website at www.lightpath.com.
Limbach Holdings (LMB)
Limbach Holdings (NASDAQ: LMB) provides commercial specialty contractor services in the United States. The company provides services in the areas of HVAC (heating, ventilation, and air-conditioning), plumbing, electrical and building controls for the design and construction of new and renovated buildings, as well as maintenance services and equipment upgrades. Its facility services comprise mechanical construction, HVAC service and maintenance, energy audits and retrofits, engineering and design build, constructability evaluation, equipment and materials selection, offsite/prefab construction, and sustainable building solutions and practices. Limbach operates from 10 strategically located business units throughout the United States, with its design engineering and innovation center, Limbach Engineering & Design Services, based in Orlando, Florida. For more information, visit the company's website at www.limbachinc.com.
Limoneira (LMNR)
Limoneira (NASDAQ: LMNR) operates as an integrated agribusiness and real estate development company in the United States and internationally. The company is devoted to sustainability with 11,200 acres of rich agricultural lands, real estate properties and water rights in California, Arizona and Chile. Headquartered in Santa Paula, California, Limoneira produces lemons, avocados, oranges, specialty citrus and other crops that are enjoyed throughout the world. For more information, visit the company's website at www.limoneira.com.
Lipocine (LPCN)
Lipocine (NASDAQ: LPCN) is a specialty pharmaceutical company that develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Lipocine's clinical development pipeline includes three development programs. TLANDO, designed to help restore normal testosterone levels in hypogonadal men, was well tolerated and met the primary efficacy end-points in phase 3 testing and is currently under FDA review. LPCN 1111 is being developed as a next-generation oral testosterone product and is currently in phase 2 testing. LPCN 1107 is a product candidate indicated for the prevention of recurrent preterm birth and is currently in phase 2 testing. LPCN 1107 has been granted Orphan Drug Designation by the FDA. For more information, visit the company's website at www.lipocine.com.
LivePerson (LPSN)
LivePerson (NASDAQ: LPSN) provides mobile and online messaging technologies that power digital communication between brands and consumers in the United States, in the United Kingdom, the Asia-Pacific, Latin America and Western Europe. Its cloud-based platform, LiveEngage, enables businesses to create a connection with consumers by offering messaging as a preferred channel of communication. LiveEngage reduces costs and increases lifetime value for more than 18,000 businesses. For more information, visit the company's website at www.liveperson.com.
LSI Industries (LYTS)
LSI Industries (NASDAQ: LYTS) ("LSI") provides corporate visual image solutions in the United States, Canada, Australia, and Latin America. The vertically integrated company develops image solutions through its lighting, graphics, and technology capabilities. LSI offers a broad range of innovative solutions for virtually any lighting or graphics application, as well as lighting and energy management control solutions to help customers manage their energy performance. The company also delivers a full range of design support, engineering, installation and project management services. Headquartered in Cincinnati, Ohio, LSI has facilities in Ohio, California, Kentucky, New York, North Carolina and Texas. For more information, visit the company's website at www.lsi-industries.com.
Lydall (LDL)
Lydall (NYSE: LDL) designs, manufactures and markets specialty engineered filtration media, industrial thermal insulating solutions, and automotive thermal and acoustical barriers for filtration/separation and thermal/acoustical applications worldwide. Headquartered in Manchester, Connecticut, the company aims to create long-term, sustainable value for employees, customers, and stockholders. Lydall's growth comes from advancing its product technology, a focused business strategy, and the commitment of its staff. For more information, visit the company's website at www.lydall.com.
Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals (NASDAQ: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal's lead candidate, MGL-3196, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist that is currently in Phase 2 development for non-alcoholic steatohepatitis (NASH) and heterozygous familial hypercholesterolemia (HeFH). For more information, visit the company's website at www.madrigalpharma.com.
MAG Silver (MAG)
MAG Silver (NYSE: MAG) is an exploration and development company that focuses on acquiring, exploring, and development of district scale projects. It explores for copper, gold, silver, lead and zinc deposits. The company has 44 percent interest in its principal focus and asset, the Juanicipio project, which comprises of a single concession covering 7,679.21 hectares located in the Fresnillo Silver Trend in Mexico, the world's premier silver mining camp. MAG Silver is currently developing the underground infrastructure on the property, with the operational expertise of its joint venture partner, Fresnillo plc, to support a 4,000 tonnes per day mining operation. MAG Silver also owns 100 percent interest in the Cinco de Mayo property where it continues to work on regaining surface access. For more information, visit the company's website at www.magsilver.com.
Matinas BioPharma (MTNB)
Matinas BioPharma (OTC: MTNB) is a clinical-stage biopharmaceutical company that focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid crystal drug delivery platform called cochleate delivery technology. Its lead anti-infective product candidates are MAT 2203 for the treatment of fungal infections and MAT2501 for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. For more information, visit the company's website at www.matinasbiopharma.com.
Mattersight (MATR)
Mattersight (NASDAQ: MATR) provides behavioral analytics services in the United States. The company provides predictive behavioral routing, performance management, quality assurance, predictive analytics, and marketing managed services that analyzes and predicts customer behavior based on the language exchanged between agents and customers during brand interactions to enhance customer satisfaction and retention, employee engagement, and operating efficiency. It serves companies in the healthcare, insurance, financial service, technology, telecommunication, cable, utility, education, hospitality and government industries. For more information, visit the company's website at www.mattersight.com.
MaxLinear (MXL)
MaxLinear (NYSE: MXL) provides radio-frequency ("RF") and mixed-signal circuits for broadband communications, data center, metro, and long-haul transport network applications worldwide. The company offers RF receivers and RF receiver systems-on-chips to receive and demodulate broadband signals, modem solutions, and physical medium devices that provide a constant current source, current-to-voltage regulation, and data alignment and retiming functionality in optical interconnect applications. Its products are integrated into a range of electronic devices, including cable and terrestrial and satellite set-top boxes and gates, DOCSIS data and voice gateways, hybrid analog and digital televisions, satellite low-noise blocker transponders or outdoor units, and physical medium devices. MaxLinear is headquartered in Carlsbad, California. For more information, visit the company's website at www.maxlinear.com.
Maxwell (MXWL)
Maxwell (NASDAQ: MXWL) develops and manufactures innovative, cost-effective energy storage and power delivery solutions. The company's ultracapacitor products provide safe and reliable power solutions for applications in consumer and industrial electronics, transportation, renewable energy and information technology. Maxwell's CONDIS® high-voltage grading and coupling capacitors help to ensure the safety and reliability of electric utility infrastructure and other applications involving transport, distribution and measurement of high-voltage electrical energy. For more information, visit the company's website at www.maxwell.com.
McEwen Mining (MUX)
McEwen Mining (NYSE: MUX) is an exploration company that develops, produces and sells gold, silver and copper ores in Argentina, Mexico, and the United States. McEwen's principal assets comprise of the San José mine in Santa Cruz, Argentina, in which the company has a 49 percent interest; the El Gallo Gold mine in Mexico; the Black Fox mine in Timmins, Canada; the Gold Bar mine in Nevada, currently under construction; and the large Los Azules copper project in Argentina, advancing towards development. For more information, visit the company's website at www.mcewenmining.com.
Medigene (MDGEF)
Medigene (OTC: MDGEF) is a biotechnology company headquartered in Martinsried near Munich, Germany. The company is focused on developing highly innovative, complementary treatment platforms to target various types and stages of cancer with a special concentration on the development of personalized T cell-based immunotherapies. The company currently has various drug candidates in clinical and pre-clinical development. For more information, visit the company's website at www.medigene.com.
MedReleaf (MEDFF)
MedReleaf (OTC: MEDFF) is a research and development ("R&D") focused certified cannabis producer in North America. MedReleaf is devoted to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers to patients seeking safe, consistent and effective medical cannabis. For more information, visit the company's name www.medreleaf.com.
Meridian Waste Solutions (MRDN)
Meridian Waste Solutions (NASDAQ: MRDN) is focused on finding and implementing solutions to solid waste needs and challenges within the industry and for its customers. Meridian Waste's core business is centered on residential and commercial waste collection and disposal but it also includes a fundamental objective to seek rewarding environmental solutions through innovation. In addition to a fleet of commercial, residential and roll off trucks, the company operates four transfer stations, one recycling facility and three municipal solid waste landfills. In addition, the company's healthcare division focuses on creating community-based synergies through collaborations and software solutions. For more information, visit the company's website at www.MWSinc.com.
Midstates Petroleum Company (MPO)
Midstates Petroleum Company (NYSE: MPO) is an independent exploration and production company focused on the application of modern drilling and completion techniques in oil and liquids-rich basins in the onshore U.S. The company's operations are currently focused on oilfields in the Mississippian Lime play in Oklahoma and the Anadarko Basin in Texas and Oklahoma. For more information, visit the company's website at www.midstatespetroleum.com.
miRagen Therapeutics (MGEN)
miRagen Therapeutics (NASDAQ: MGEN) is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs. The company's MRG-106 is a clinical product candidate for the treatment of certain cancers. miRagen's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as systemic sclerosis. The company is also developing MRG-110 for the treatment of heart failure and other ischemic disease. miRagen's translational medicine strategy is to progress rapidly to first-in-human studies once it has established the pharmacokinetics, pharmacodynamic, safety and manufacturability of the product candidate in preclinical studies. For more information, visit the company's website at www.miragen.com.
MobileIron (MOBL)
MobileIron (NASDAQ: MOBL) provides a purpose-built mobile IT platform that enables enterprises to secure and manage mobile applications, content, and devices while providing their employees with device choice, privacy, and a native user experience. The company's innovative MobileIron platform offers enterprise mobility management ("EMM") solution that configures and delivers applications to smartphones, tablets, laptops, and desktops running operating systems, such as Android, iOS, macOS, and Windows 10; and secures data-at-rest and data-in-motion on modern endpoints and across the corporate network, as well as secures access to back-end corporate networks and cloud services. The company serves financial service, government, healthcare, legal, manufacturing, professional service, retail, technology, and telecommunication industries in the United States and internationally. MobileIron, Inc. is headquartered in Mountain View, California. For more information, visit the company's website at www.mobileiron.com.
Moleculin Biotech (MBRX)
Moleculin Biotech (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. The company's lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin also has WP1066 in development, which is a modulator of hard-to-target tumor cell signaling mechanisms intended to attack tumor activity directly while also recruiting the patient's own immune system. In addition, the company is engaged in the preclinical development of additional drug candidates including compounds targeting the metabolism of tumors. For more information, visit the company's website at www.moleculin.com.
Monaker Group (MKGI)
Monaker Group (NASDAQ: MKGI) is a technology-driven travel company focused on delivering innovation to alternative lodging rentals (ALR) market. The Monaker Booking Engine (MBE) delivers instant booking of more than one million vacation rental homes, villas, chalets, apartments, condos, resort residences and castles. MBE offers travel distributors and agencies an industry-first: a customizable, instant-booking platform for alternative lodging. For more information, visit the company's website at www.monakergroup.com.
Motorcar Parts of America (MPAA)
Motorcar Parts of America (NASDAQ: MPAA) is a remanufacturer, manufacturer and distributor of automotive aftermarket parts -- including alternators, starters, wheel bearing and hub assemblies, brake master cylinders, brake power boosters and turbochargers utilized in imported and domestic passenger vehicles, light trucks and heavy-duty applications. The company also designs and manufactures test equipment for performance, endurance and production testing of alternators, starters, electric motors, inverters and belt starter generators for both the OE and aftermarket. Motorcar Parts of America's products are sold to automotive retail outlets and the professional repair market throughout the United States and Canada. For more information, visit the company's website at www.motorcarparts.com.
My Size (MYSZ)
My Size (NASDAQ: MYSZ) is a technology company that has developed a unique measurement technology based on sophisticated algorithms and cutting-edge technology with broad applications including the apparel, e-commerce, DIY, shipping and parcel delivery industries. This proprietary, innovative technology is driven by several algorithms which are able to calculate and record measurements in a variety of novel ways. The company's MySizeID application empowers consumers to create a secure online profile of their personal measurements to get the right fit. The company's SizeUp app enables users to utilize their smartphone as a tape measurer. For more information, visit the company's website at www.mysizeid.com.
Myomo (MYO)
Myomo (NYSE: MYO) is a commercial-stage medical robotics company that provides expanded mobility solutions for individuals suffering from neurological disorders and upper limb paralysis in the United States. Myomo develops and markets the MyoPro product line, a powered upper limb orthosis designed to restore function to the weakened or paralyzed arms of patients suffering from disease or injury. It is currently the only marketed device that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to complete activities of daily living, including feeding themselves, carrying objects and doing household tasks. For more information, visit the company's website at www.myomo.com.
Nanotech Security (NTSFF)
Nanotech Security (TSX-V: NTS) (OTC: NTSFF) is engaged in designing, manufacturing and marketing nano-optic products that have application for brand protection and enhancement across a broad array of markets. The company utilizes its advanced nanotechnology to help combat the global problem of counterfeiting, offering advanced authentication products that help prevent the counterfeiting of banknotes, tax stamps, secure government documents, commercial branding, pharmaceutical products and more. For more information, visit the company's website at www.nanosecurity.ca.
Natus Medical (BABY)
Natus Medical (NASDAQ: BABY) is a provider of a newborn care and neurology healthcare products and services used in screening, diagnosing, detecting, treating, monitoring and tracking common medical problems in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The company was founded in 1989, and its products are used in hospitals, clinics and laboratories throughout the world. For more information, visit the company's website at www.natus.com.
Nemaska Lithium (NMKEF)
Nemaska Lithium (TSX: NMX) (OTC: NMKEF) is a Canada-based lithium company focused on becoming a lithium hydroxide and lithium carbonate supplier to the lithium battery market, which is largely driven by electric vehicles. The company is located in the mining-friendly jurisdiction of Quebec, Canada, and has received a notice of allowance for a main patent application on its proprietary process for lithium hydroxide and lithium carbonate production. The company is pursuing patent protection for this process in various global jurisdictions. Nemaska Lithium is also developing one of the world's richest spodumene hard rock lithium deposits, both in terms of volume and grade. For more information, visit the company's website at www.nemaskalithium.com.
Neogen (NEOG)
Neogen (NASDAQ: NEOG) is focused on developing, manufacturing and marketing a variety of products and services dedicated to food and animal safety. The company operates two segments: food safety and animal safety. Its food safety division produces and markets diagnostic test kits and related products that are utilized by food producers and processors for the detection of harmful natural toxins, foodborne bacteria, allergens and general sanitation levels. The company's animal safety division is a leading developer of animal genomics and also manufactures and distributes an array of animal healthcare products. For more information, visit the company's website at www.neogen.com.
NeoGenomics (NEO)
NeoGenomics (NASDAQ: NEO) provides cancer genetics testing and information services, offering one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. The company is engaged in serving the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks and managed care organizations throughout the United States. NeoGenomics also operates a Pharma Services division that serves pharmaceutical clients in clinical trials and drug development. For more information, visit the company's website at www.neogenomics.com.
New Age Beverages (NBEV)
New Age Beverages (NASDAQ: NBEV) is a healthy functional beverage company that competes in the rapidly growing healthy functional beverage segments, including ready-to-drink (RTD) tea, RTD coffee, kombucha, energy drinks, relaxation drinks, coconut waters and functional waters. Since its creation, the company has become the 54th-largest beverage company and the eighth-largest healthy beverage company in the world. Its brands are sold throughout all 50 states and in more than 10 countries and include XingTea®, Marley One Drop®, Búcha® Live Kombucha, XingEnergy®, Marley Mellow Mood®, Marley Mate™, Coco-Libre®, and Aspen Pure® PH and Aspen Pure® Probiotic Water. For more information, visit the company's website at www.newagebev.com.
New Pacific Metals (NUPMF)
New Pacific Metals (TSX-V: NUAG) (OTC: NUPMF) is a Canada-based exploration and development company engaged in exploring and developing precious metal mining properties in Bolivia, Canada and China. The company's flagship project is the Silver Sand Project, located in the Potosí Department of Bolivia, and New Pacific additionally owns the Tagish Lake Gold Project in Yukon, Canada, and the RZY Project in Qinghai Province, China. The company's largest shareholders include Silvercorp Metals Inc. (SVM), which is China's largest primary silver producer, and Pan American Silver Corp. (PAAS), which is one of the largest primary silver producers in the world. For more information, visit the company's website at www.newpacificmetals.com.
Ocean Power Technologies (OPTT)
Ocean Power Technologies (NASDAQ: OPTT) aims to change the world through lasting, pioneering and cost-effective ocean energy solutions. The company's PB3 PowerBuoy utilizes ocean waves to deliver clean, reliable and persistent electric power as well as real-time communications for remote offshore applications in markets like oil and gas, defense, security, ocean observing and communications. Ocean Power Technologies is headquartered in New Jersey. For more information, visit the company's website at www.oceanpowertechnologies.com.
Onconova Therapeutics (ONTX)
Onconova Therapeutics (NASDAQ: ONTX) is a phase 3 clinical-stage biopharmaceutical company engaged in the discovery and development of novel small molecule drug candidates to treat cancer. The company's primary focus is on myelodysplastic syndromes (MDS). Its lead candidate, Rigosertib, is a proprietary phase 3 small molecule agent that the company believes is able to block cellular signaling by targeting RAS effector pathways. Utilizing a proprietary chemistry platform, Onconova has developed a pipeline of targeted agents that are designed to work against specific cellular pathways important in cancer cells. The company currently has three product candidates in the clinical stage and several preclinical programs. For more information, visit the company's website at www.onconova.com.
On Assignment (ASGN)
On Assignment (NYSE: ASGN) is one of the foremost providers of IT and professional services in the technology, creative/digital, engineering and life sciences sectors. Through an integrated suite of professional staffing and IT solutions, On Assignment improves productivity and utilization among leading corporate enterprises. The company is viewed as best in class across multiple industries and has built an outstanding reputation of excellence over the past 33 years. Based in Calabasas, California, On Assignment operates a network of over 150 branch offices across the United States, Canada and Europe. For more information, visit the company's website at www.onassignment.com.
One Stop Systems (OSS)
One Stop Systems (NASDAQ: OSS) is a provider of high-performance compute accelerators, flash storage arrays and customized servers for deep learning, artificial intelligence, defense, finance and entertainment applications. The company uses the power of PCI Express, the latest GPU accelerators and NVMe flash cards to build award-winning systems—including various industry firsts—for OEMs and government clients. OSS's groundbreaking hardware and Ion Accelerator Software offer outstanding performance and unmatched scalability. The company's products are offered directly as well as through global distributors and its SkyScale cloud services. For more information, visit the company's website at www.onestopsystems.com.
OptimizeRx® (OPRX)
OptimizeRx® (OTC:OPRX) is the nation's leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company's cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information. The company's network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more than half a million healthcare providers access to these benefits within their workflow at the point of care. For more information, visit the company's website at www.optimizerx.com.
ORBCOMM (ORBC)
ORBCOMM (NASDAQ: ORBC) is a global leader and innovator in the industrial Internet of Things, providing solutions that connect businesses to their assets to deliver increased visibility and operational efficiency. The company offers a broad set of asset monitoring and control solutions, including seamless satellite and cellular connectivity, unique hardware and powerful applications, all backed by end-to-end customer support, from installation to deployment to customer care. ORBCOMM has a diverse customer base including premier OEMs, solutions customers and channel partners spanning transportation, supply chain, warehousing and inventory, heavy equipment, maritime, natural resources, and government. For more information, visit the company's website at www.orbcomm.com.
OSI Systems (OSIS)
OSI Systems (NASDAQ: OSIS) is a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications in the homeland security, healthcare, defense and aerospace industries. The company boasts more than four decades of electronics engineering and manufacturing experience and has offices and production facilities in over a dozen countries. OSI Systems is implementing a strategy of expansion into selective end-product markets. The company has three operating divisions: a security division, a healthcare division, and an optoelectronics and manufacturing division. For more information, visit the company's website at www.osi-systems.com.
OTC Markets Group (OTCM)
OTC Markets Group (OTC: OTCM) operates financial markets for 10,000 U.S. and global securities, including the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market. Through OTC Link® ATS, a varied network is connected, comprised of broker-dealers that offer liquidity and execution services. OTC Markets Group enables investors to trade easily through the broker of their choice and empowers companies to enhance the quality of information available to investors. OTC Market Group offers services in three central areas: trading services, market data and corporate services. For more information, visit the company's website at www.otcmarkets.com.
